LXRX News and Press, Lexicon Pharmaceuticals Inc. From 05/26/23

2023-05-26 08:34:32 ET Onfolio Holdings ( ONFO ) +62% Completes Development of Generative AI Search Tool. Elevation Oncology ( ELEV ) +58% . Quhuo Limited ( QH ) +37% Sector Exceeded RMB12 Million in Sales During the Labor Day Holiday, Achieving Impre...

2023-05-19 14:38:24 ET Summary Lexicon ought to find out whether its heart failure candidate sotafligozin will be approved on May 27. The drug has been rejected before - in 2019, in patients with Type 1 diabetes, on safety grounds. Astrazeneca's Farxiga and Lilly's Jardiance h...

2023-05-11 06:50:00 ET Thanks to what could be a looming regulatory approval, shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are soaring, rising by 33% in the last 30 days and 74% over the last 12 months. Wall Street analysts are on average quite bullish, with the average year-ahe...

Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study Sotagliflozin NDA for treatment of heart failure on track for May 27, 2023 PDUFA action date THE WOODLANDS, Te...

2023-05-02 20:27:08 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Results Conference Call May 02, 2023 05:00 PM ET Company Participants Carrie Siragusa - Executive Director, Corporate Strategy and Investor Relations Lonnel Coats - Chief Executive Officer Jeff W...

2023-05-02 16:32:38 ET Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q1 GAAP EPS of -$0.17 beats by $0.01 . Revenue of $0.02M (-50.0% Y/Y) misses by $0.01M . For further details see: Lexicon Pharmaceuticals GAAP EPS of -$0.17 beats by $0.01, rev...

NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m...

2023-04-22 08:15:00 ET Biotech companies yet to generate revenue are some of the riskiest growth stocks out there, but if you can invest in one while it's taking off, your portfolio will thank you. On that note, according to analysts on Wall Street, shares of Lexicon Pharmaceuticals ...